Alembic Pharmaceuticals is currently trading at Rs. 544.05, up by 6.85 points or 1.28% from its previous closing of Rs. 537.20 on the BSE.
The scrip opened at Rs. 545.00 and has touched a high and low of Rs. 547.95 and Rs. 544.05 respectively. So far 105 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 636.50 on 03-Dec-2018 and a 52 week low of Rs. 435.10 on 21-Jun-2019.
Last one week high and low of the scrip stood at Rs. 565.00 and Rs. 523.00 respectively. The current market cap of the company is Rs. 10256.21 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 15.97% and 11.06% respectively.
Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceuticals (Aleor) has received approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desonide Ointment, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Ointment, 0.05%, of Perrigo New York, Inc. Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Desonide Ointment, 0.05%, has an estimated market size of $13 million for twelve months ending December 2018 according to IQVIA. Alembic has a cumulative total of 105 ANDA approvals (93 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1529.55 |
Dr. Reddys Lab | 6315.00 |
Cipla | 1423.40 |
Zydus Lifesciences | 1021.00 |
Lupin | 1679.75 |
View more.. |